Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Sandrine Marchais-Oberwinkler"'
Publikováno v:
Molecules, Vol 18, Iss 4, Pp 4487-4509 (2013)
In this study, a series of conformationally restricted thieno[3,2-d]pyrimidinones, thieno[3,2-d]pyrimidines and quinazolinones was designed and synthesized with the goal of improving the biological activity as 17b-hydroxysteroid dehydrogenase type 2
Externí odkaz:
https://doaj.org/article/44a8faa8cf2a4f78bd3d77197f9fd589
Autor:
Rolf W. Hartmann, Chris J. van Koppen, Matthias W. Laschke, Giuseppe Felice Mangiatordi, Ahmed S. Abdelsamie, Martin Frotscher, Orazio Nicolotti, Abdelrahman Mohamed, Angelo Carotti, Arcangela Mazzini, Hanna Drzewiecka, Emanuele M. Gargano, Paweł P. Jagodziński, Sandrine Marchais-Oberwinkler
Publikováno v:
ACS medicinal chemistry letters
United States
ACS Med Chem Lett
ACS medicinal chemistry letters (2021). doi:10.1021/acsmedchemlett.1c00462
info:cnr-pdr/source/autori:Emanuele M. Gargano, Abdelrahman Mohamed, Ahmed S. Abdelsamie, Giuseppe F. Mangiatordi, Hanna Drzewiecka, Pawe? P. Jagodzi?ski, Arcangela Mazzini, Chris J. van Koppen, Matthias W. Laschke, Orazio Nicolotti, Angelo Carotti, Sandrine Marchais-Oberwinkler, Rolf W. Hartmann, and Martin Frotscher/titolo:17?-Hydroxysteroid Dehydrogenase Type 1 Inhibition: A Potential Treatment Option for Non-Small Cell Lung Cancer/doi:10.1021%2Facsmedchemlett.1c00462/rivista:ACS medicinal chemistry letters/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume
United States
ACS Med Chem Lett
ACS medicinal chemistry letters (2021). doi:10.1021/acsmedchemlett.1c00462
info:cnr-pdr/source/autori:Emanuele M. Gargano, Abdelrahman Mohamed, Ahmed S. Abdelsamie, Giuseppe F. Mangiatordi, Hanna Drzewiecka, Pawe? P. Jagodzi?ski, Arcangela Mazzini, Chris J. van Koppen, Matthias W. Laschke, Orazio Nicolotti, Angelo Carotti, Sandrine Marchais-Oberwinkler, Rolf W. Hartmann, and Martin Frotscher/titolo:17?-Hydroxysteroid Dehydrogenase Type 1 Inhibition: A Potential Treatment Option for Non-Small Cell Lung Cancer/doi:10.1021%2Facsmedchemlett.1c00462/rivista:ACS medicinal chemistry letters/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume
[Image: see text] In the face of the clinical challenge posed by non-small cell lung cancer (NSCLC), the present need for new therapeutic approaches is genuine. Up to now, no proof existed that 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b72b1eb9a0d3948ea61df325c6e341e
https://hdl.handle.net/10033/623149
https://hdl.handle.net/10033/623149
Autor:
Emanuele M Gargano, Giuseppe Allegretta, Enrico Perspicace, Angelo Carotti, Chris Van Koppen, Martin Frotscher, Sandrine Marchais-Oberwinkler, Rolf W Hartmann
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0134754 (2015)
Design and synthesis of a new class of inhibitors for the treatment of osteoporosis and its comparative h17β-HSD2 and m17β-HSD2 SAR study are described. 17a is the first compound to show strong inhibition of both h17β-HSD2 and m17β-HSD2, intracel
Externí odkaz:
https://doaj.org/article/0bc4d2b54c854517a63ff00bf9fcb5c9
Autor:
Nicole Bertoletti, Aline Keils, Sandrine Marchais-Oberwinkler, Gerhard Klebe, Andreas Heine, Mohammed J. Badran
Publikováno v:
The Journal of Steroid Biochemistry and Molecular Biology. 189:135-144
17β-Hydroxysteroid dehydrogenase type 14 (17β-HSD14) catalyzes the conversion of highly active estrogens and androgens into their less active oxidized forms in presence of NAD+ as cofactor. The crystal structure of 17β-HSD14 has been determined, h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86adecf4ffb8f73d2261c051fb5d72b8
https://doi.org/10.1016/j.jsbmb.2019.02.009
https://doi.org/10.1016/j.jsbmb.2019.02.009
Autor:
Alessandro Spadaro, Matthias Negri, Sandrine Marchais-Oberwinkler, Emmanuel Bey, Martin Frotscher
Publikováno v:
PLoS ONE, Vol 7, Iss 1, p e29252 (2012)
17β-estradiol (E2), the most potent estrogen in humans, known to be involved in the development and progession of estrogen-dependent diseases (EDD) like breast cancer and endometriosis. 17β-HSD1, which catalyses the reduction of the weak estrogen e
Externí odkaz:
https://doaj.org/article/8b5b42ff1bff47bcaee02bfde7a2d7c2
Autor:
Lorenz Siebenbuerger, Sandrine Marchais-Oberwinkler, Michael D. Menger, Martin Frotscher, Ahmed S. Abdelsamie, Carsten Boerger, Rolf W. Hartmann, Victor Hernandez-Olmos, Claudia Scheuer, Chris J. van Koppen, Matthias W. Laschke
Publikováno v:
Journal of Medicinal Chemistry. 61:10724-10738
Intracellular elevation of E2 levels in bone by inhibition of 17β hydroxysteroid dehydrogenase type 2 (17β-HSD2) without affecting systemic E2 levels is an attractive approach for a targeted therapy against osteoporosis, a disease which is characte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3a7ff0cde1f64d87d00e9445907fc28
https://doi.org/10.1021/acs.jmedchem.8b01373
https://doi.org/10.1021/acs.jmedchem.8b01373
Autor:
Martin Frotscher, Ahmed S. Abdelsamie, Rolf W. Hartmann, Sebastian Müller, Sandrine Marchais-Oberwinkler, Chris J. van Koppen, Matthias W. Laschke, Lorenz Siebenbürger, Mohamed Salah, Ahmed Merabet, Claudia Scheuer, Oliver Zierau, Michael D. Menger, Günter Vollmer
Publikováno v:
Journal of medicinal chemistry. 62(15)
Osteoporosis is predominantly treated with drugs that inhibit further bone resorption due to estrogen deficiency. Yet, osteoporosis drugs that not only inhibit bone resorption but also stimulate bone formation, such as potentially inhibitors of 17β-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ab02369095497d2b4ea68f6ffabf214
https://pubmed.ncbi.nlm.nih.gov/31343176
https://pubmed.ncbi.nlm.nih.gov/31343176
Autor:
Rolf W. Hartmann, Sebastian Müller, Ahmed S. Abdelsamie, Ahmed Merabet, Oliver Zierau, Sophie Pählig, Günter Vollmer, Sandrine Marchais-Oberwinkler, Chris J. van Koppen
Publikováno v:
The Journal of steroid biochemistry and molecular biology. 192
Hormone replacement therapy is a viable option to protect bone from postmenopausal osteoporosis. Systemically elevated estrogen levels, however, are disadvantageous because of the risk of harmful side effects in other organs. The rationale of the stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aed4593cfc0c68897f5617fd778f1e46
https://pubmed.ncbi.nlm.nih.gov/31185280
https://pubmed.ncbi.nlm.nih.gov/31185280
Autor:
Michael D. Menger, Martin Frotscher, Lorenz Siebenbürger, Matthias W. Laschke, Rolf W. Hartmann, Carsten Börger, Steven C. Herath, Mohamed Salah, Yannik Biskupek, Tim Pohlemann, Ahmed S. Abdelsamie, Claudia Scheuer, Sandrine Marchais-Oberwinkler, Chris J. van Koppen
Publikováno v:
Journal of medicinal chemistry. 62(3)
Current therapies of steroid hormone-dependent diseases predominantly alter steroid hormone concentrations (or their actions) in plasma, in target and nontarget tissues alike, rather than in target organs only. Targeted therapy through the inhibition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::936062b4a4834811593a989e57dd5b07
https://pubmed.ncbi.nlm.nih.gov/30645111
https://pubmed.ncbi.nlm.nih.gov/30645111
Autor:
Pauline Banachowicz, Rolf W. Hartmann, Susanne Maria Weber, Christoph P. Sager, Matthias Negri, Gabriele Möller, Sandrine Marchais-Oberwinkler, Jerzy Adamski
Publikováno v:
The Journal of Steroid Biochemistry and Molecular Biology. 206:105790
17β-Hydroxysteroid dehydrogenase type 2 (17β-HSD2) catalyzes the conversion of highly active estrogens and androgens into their less active forms using NAD+ as cofactor. Substrate and cofactor specificities of 17β-HSD2 have been reported and poten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fd1b40b75a21e82ee7d608eec4ef80e
https://doi.org/10.1016/j.jsbmb.2020.105790
https://doi.org/10.1016/j.jsbmb.2020.105790